These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 30653705)

  • 1. Intensification patterns and the probability of HbA
    Pantalone KM; Misra-Hebert AD; Hobbs TM; Ji X; Kong SX; Milinovich A; Weng W; Bauman JM; Ganguly R; Burguera B; Kattan MW; Zimmerman RS
    Diabet Med; 2020 Jul; 37(7):1114-1124. PubMed ID: 30653705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term sustainability of glycaemic achievements with second-line antidiabetic therapies in patients with type 2 diabetes: A real-world study.
    Montvida O; Shaw JE; Blonde L; Paul SK
    Diabetes Obes Metab; 2018 Jul; 20(7):1722-1731. PubMed ID: 29536608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of intensification therapies in Danes with Type 2 diabetes who use basal insulin: a population-based study.
    Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
    Diabet Med; 2017 Feb; 34(2):213-222. PubMed ID: 27279380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment intensification for patients with type 2 diabetes and poor glycaemic control.
    Fu AZ; Sheehan JJ
    Diabetes Obes Metab; 2016 Sep; 18(9):892-8. PubMed ID: 27160505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Slow Titration and Delayed Intensification of Basal Insulin Among Patients with Type 2 Diabetes.
    Mocarski M; Yeaw J; Divino V; DeKoven M; Guerrero G; Langer J; Thorsted BL
    J Manag Care Spec Pharm; 2018 Apr; 24(4):390-400. PubMed ID: 29406841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal changes in glycated haemoglobin following treatment intensification after inadequate response to two oral antidiabetic agents in patients with type 2 diabetes.
    Kim K; Unni S; Brixner DI; Thomas SM; Olsen CJ; Sterling KL; Mitchell M; McAdam-Marx C
    Diabetes Obes Metab; 2019 Jul; 21(7):1725-1733. PubMed ID: 30848039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical inertia in patients with type 2 diabetes treated with oral antidiabetic drugs: Results from a Japanese cohort study (JDDM53).
    Maegawa H; Ishigaki Y; Langer J; Saotome-Nakamura A; Andersen M;
    J Diabetes Investig; 2021 Mar; 12(3):374-381. PubMed ID: 32643314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin.
    Khunti K; Nikolajsen A; Thorsted BL; Andersen M; Davies MJ; Paul SK
    Diabetes Obes Metab; 2016 Apr; 18(4):401-9. PubMed ID: 26743666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glycaemic control after treatment intensification in patients with type 2 diabetes uncontrolled on two or more non-insulin antidiabetic drugs in a real-world setting.
    Canivell S; Mata-Cases M; Real J; Franch-Nadal J; Vlacho B; Khunti K; Gratacòs M; Mauricio D
    Diabetes Obes Metab; 2019 Jun; 21(6):1373-1380. PubMed ID: 30756446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting.
    Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
    Curr Med Res Opin; 2018 Jun; 34(6):1125-1133. PubMed ID: 29557199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients.
    Montvida O; Klein K; Kumar S; Khunti K; Paul SK
    Diabetes Obes Metab; 2017 Jan; 19(1):108-117. PubMed ID: 27629433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
    Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
    Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of time to treatment intensification on glycemic goal attainment among patients with type 2 diabetes failing metformin monotherapy.
    Rajpathak SN; Rajgopalan S; Engel SS
    J Diabetes Complications; 2014; 28(6):831-5. PubMed ID: 25104238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors Associated with Diabetes-Related Clinical Inertia in a Managed Care Population and Its Effect on Hemoglobin A1c Goal Attainment: A Claims-Based Analysis.
    Ruiz-Negrón N; Wander C; McAdam-Marx C; Pesa J; Bailey RA; Bellows BK
    J Manag Care Spec Pharm; 2019 Mar; 25(3):304-313. PubMed ID: 30816810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
    Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
    Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elucidating the role of weight loss and glycaemic control in patients with type 2 diabetes.
    Sharma A; Mariam A; Zacherle E; Milinovich A; Bauman J; Sugano DS; Noone J; Rajpura JR; Zimmerman RS; Burguera B; Kattan MW; Misra-Hebert AD; Pantalone KM; Rotroff DM
    Diabetes Obes Metab; 2024 Nov; 26(11):5347-5357. PubMed ID: 39192531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical inertia in basal insulin-treated patients with type 2 diabetes - Results from a retrospective database study in Japan (JDDM 43).
    Satoh J; Andersen M; Bekker Hansen B; Larsen Thorsted B; Tutkunkardas D; Zacho M; Maegawa H
    PLoS One; 2018; 13(9):e0198160. PubMed ID: 30226870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of glucagon-like peptide-1 receptor agonists among individuals on basal insulin requiring treatment intensification.
    Trautmann ME; Vora J
    Diabet Med; 2018 Jun; 35(6):694-706. PubMed ID: 29478255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early glycaemic control in metformin users receiving their first add-on therapy: a population-based study of 4,734 people with type 2 diabetes.
    Thomsen RW; Baggesen LM; Søgaard M; Pedersen L; Nørrelund H; Buhl ES; Haase CL; Johnsen SP
    Diabetologia; 2015 Oct; 58(10):2247-53. PubMed ID: 26277380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of Treatment Intensification on A1c in Patients with Suboptimally Controlled Type 2 Diabetes After 2 Oral Antidiabetic Agents.
    Kim K; Unni S; McAdam-Marx C; Thomas SM; Sterling KL; Olsen CJ; Johnstone B; Mitchell M; Brixner D
    J Manag Care Spec Pharm; 2019 Mar; 25(3):314-322. PubMed ID: 30816811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.